Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
13.13
+1.24 (10.43%)
At close: May 8, 2025, 4:00 PM
13.13
0.00 (0.00%)
After-hours: May 8, 2025, 4:00 PM EDT
Bicara Therapeutics Employees
Bicara Therapeutics had 55 employees as of December 31, 2024.
Employees
55
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,236,273
Market Cap
716.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCAX News
- 10 days ago - Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 - GlobeNewsWire
- 15 days ago - Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 19 days ago - Bicara: Innovative Precision Tumor Targeting - Seeking Alpha
- 6 weeks ago - Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - GlobeNewsWire
- 3 months ago - Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire